Loading...
Rituximab therapy in pemphigus and other autoantibody-mediated diseases
Rituximab, a monoclonal antibody targeting the B cell marker CD20, was initially approved in 1997 by the United States Food and Drug Administration (FDA) for the treatment of non-Hodgkin lymphoma. Since that time, rituximab has been FDA-approved for rheumatoid arthritis and vasculitides, such as gra...
Saved in:
| Published in: | F1000Res |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
F1000Research
2017
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5288686/ https://ncbi.nlm.nih.gov/pubmed/28184292 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12688/f1000research.9476.1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|